Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer

• Main Authors: Yutaka Yoneoka (Author), Tsukuru Amano (Author), Akimasa Takahashi (Author), Hiroki Nishimura (Author), Mari Deguchi (Author), Hiroyuki Yamanaka (Author), Yuji Tanaka (Author), Shunichiro Tsuji (Author), Takashi Murakami (Author)
• Format: Book
• Published: Korean Society of Obstetrics and Gynecology, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective There is no consensus on whether platinum doublet chemotherapy or lenvatinib and pembrolizumab (LEN/PEM) is superior for advanced or recurrent endometrial cancer. Thus, this study aimed to compare the prognosis and adverse events in patients with advanced or recurrent endometrial cancer tr...